|
OncologyPharmacist.net Where Oncology Pharmacists, Residents, & Technicians access Chemotherapy Drug Information, Products, & Programs |
WelcomeOncologyPharmacist.NET is dedicated to providing timely information, consulting services, and links for Clinical Hem/Onc/BMT Pharmacists, Residents, and Technicians, in a single location, to be used on a daily basis. Improving Patient Care through the exchange of information is our goal. Our News and Clinical Tools sections will come from practice sites throughout the world. Our Job Boards will focus on relevant positions exclusively. Our Patient Assistant Programs area will link to sites that provide drugs that are used strictly in Hematology and Oncology. New Drugs will highlight Chemotherapy and Supportive Care drugs with new indications within the last 365 days. Our hope is to integrate CMS coding and announcements in the future as well as provide an area for Hem/Onc/BMT Residents, Technicians, and Practitioners to exchange ideas. Please bookmark our site, sign up to be listed on our Advisory Board Clinicians or Speakers List, send us suggestions or guidelines to improve the site, and consider advertising in this exciting domain. OP Links of Interest
www.usp.org CSP and chemo safety guidelines
www.jointcommission.org Safety goals www.nccn.org Chemo guidelines www.asco.org Chemo guidelines www.ashp.org Chemo and safety guidelines www.pharmecology.com Wast Stream Management Guidelines www.fda.gov/Safety/MedWatch/default.htm MedWatch reporting program oncologypharmacist.net Consulting services and practice sites www.hoparx.org Hematology/Oncology Pharmacy Association chemorders.com Chemotherapy Order Templates Postmarket Safety Information For Patients and Providers anti-cancerdrugs.com Lippincott Williams & Wilkins BioMedSearch.com Biomedical Search Engine Newsfeed Cancer / Oncology News From Medical News TodayLatest Health News and Medical News posted throughout the day, every day. Discovery Alters Prevailing View Of Splicing Regulation And Has Implications ... There are always exceptions to a rule, even one that has prevailed for more than three decades, as demonstrated by a Cold Spring Harbor Laboratory (CSHL) study on RNA splicing, a cellular editing process... Glioblastoma Classification Revision Should Improve Patient Care Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors. The outdated system was devised for glioblastoma and related brain tumors that were treated by radiation therapy only, and it relied on clinical signs and symptoms... Patients With Muscle-Invasive Bladder Cancer Benefit From Accelerated Chemoth... For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery... Positive Survival Trend Seen In Phase I Study Of Temsirolimus, Capecitabine A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients... Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib... Newsfeed display by CaRP  |
| Headquarters: Warwick, RI • ©2009 OncologyPharmacist.net |